[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2005081171A2 - Calculateur de bol d'insuline pour dispositif de communications mobiles - Google Patents

Calculateur de bol d'insuline pour dispositif de communications mobiles Download PDF

Info

Publication number
WO2005081171A2
WO2005081171A2 PCT/ZA2005/000040 ZA2005000040W WO2005081171A2 WO 2005081171 A2 WO2005081171 A2 WO 2005081171A2 ZA 2005000040 W ZA2005000040 W ZA 2005000040W WO 2005081171 A2 WO2005081171 A2 WO 2005081171A2
Authority
WO
WIPO (PCT)
Prior art keywords
ets
insulin
parameters
blood glucose
person
Prior art date
Application number
PCT/ZA2005/000040
Other languages
English (en)
Other versions
WO2005081171A3 (fr
Inventor
Edward Henry Mathews
Original Assignee
Edward Henry Mathews
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edward Henry Mathews filed Critical Edward Henry Mathews
Publication of WO2005081171A2 publication Critical patent/WO2005081171A2/fr
Publication of WO2005081171A3 publication Critical patent/WO2005081171A3/fr

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation

Definitions

  • This invention relates to the fields of diabetes management. It relates in. particular to a mobile phone based application to calculate the type and magnitude of action necessary to control blood glucose levels. It also relates to a method of operation of such a system.
  • Equivalent Teaspoon Sugar means an energy unit used for quantifying energy in food and energy usage in exercise.
  • ets can also be used to quantify energy being expended during exercise by relating the energy to the effective energy available in a teaspoon sugar, ets can also be used to express any quantity of energy e.g. the blood glucose energy in the blood or the amount of glycogen energy stored in the liver.
  • insulin includes within its scope any blood sugar regulatory substance.
  • diabetes or diabetic refers to Type 1 diabetes or Type 1 diabetic respectively unless otherwise stated.
  • IDDM Insulin Dependant Diabetes Mellitus
  • Type I Diabetes is the condition where the islets of Langerhans can no longer supply the body with the hormone Insulin.
  • Insulin is needed by the human body to help control blood glucose levels. When consuming food containing carbohydrates (CHO) the blood glucose levels will rise. Insulin is then needed to lower the blood glucose level back to an acceptable level again by storing glucose as glycogen. Insulin is also needed by the cells to utilize the energy of the sugar in the blood. It is therefore necessary for patients with IDDM to monitor and control their blood glucose levels by administering insulin. This will help keep their blood glucose levels under a safe range preventing hypoglycemia and hyperglycemia.
  • hypoglycemia occurs when the blood glucose level falls too low while hyperglycemia is the result of high blood glucose levels. Hypoglycemia has a more immediate or short-term threat to the diabetic, which can cause comas, seizures or even death. Hyperglycemia's effects become evident after a longer term of elevated blood glucose levels.
  • diabetics are following rigid daily schedules concerning their meals, exercises and insulin administrations. This makes it difficult for IDDM diabetics to calculate their insulin requirements when eating different meals or doing irregular extra exercises.
  • the main objective of this invention will be to calculate the type and measure of the corrective action needed at a given time to control the diabetic's blood glucose level within a safe range.
  • the device will take into account the current blood glucose level, immediate food intake, exercise within 6 hours and several parameters measured on the individual patient.
  • the main advantages of this implementation are the very low cost of the device and also the high accuracy of the prediction algorithm discussed in the description.
  • the application for mobile phone will also be a great educational tool to teach diabetics the dynamics involved in their blood glucose control. Further objectives and advantages will be mentioned in the description.
  • FIG. 1 shows the block diagram of the mobile phone Insulin bolus calculation device.
  • FIG. 2 shows the typical blood glucose response of a Type 1 diabetic after consuming a meal containing carbohydrates.
  • FIG. 3 shows the typical blood glucose response of a Type 1 diabetic after administering short acting insulin.
  • FIG. 4 shows the increase in blood glucose (for Type 1 diabetics) to ets intake as piecewise linear function with two sections.
  • This present invention is a system using a new method to help patients with IDDM to calculate the type and measure of corrective action needed to control their blood glucose levels within a safe range.
  • ets is a new generic energy unit
  • ets is the abbreviation for Equivalent Teaspoons Sugar.
  • This energy unit can be used to quantify energy in food and energy usage in exercise. Quantifying food in ets, the effect that food intake will have on blood glucose levels for a specific person, can be predicted. The blood sugar response after a meal will be predicted by using the amount of ets in the meal. Exercises can also be quantified in ets for the individual. This is very useful in calculating appropriate insulin doses for Type I diabetics. In general the blood glucose , level rise for a type 1 diabetic is dependent upon the ets intake as shown in Figure 4. The gradient or sensitivity to ets is a person specific factor and can easily be measured.
  • the characterisation method used by the invention is based on the ets concepts. Characterisation is necessary in order to customize these products for the individual diabetic user. The effect that ets intake has on the increase of blood glucose concentration for the diabetic is approximated by a linear function.
  • the ets sensitivity value EC can be calculated performing the simple test procedure to determine the individuals blood glucose increase per unit ets consumed- At high levels of ets inta e, the ets sensitivity (EC) decreases.
  • the blood glucose response for ets intake can generally be approximated by two piecewise linear continuous functions shown in FIG. 4. Typical patients eating healthy will normally stay within the first part of the approximation function therefore simplifying blood glucose response prediction with a single linear function.
  • FIG. 2 shows a typical blood glucose response of a Type I diabetic after eating a meal containing carbohydrates.
  • the meal is ingested after fasting for six hours or longer.
  • the time of the meal is taken as 0 minutes (15).
  • the ets sensitivity test is performed after a six hour fast to eliminate the effects of the previous meal and previous short acting insulin injection. By this time the blood glucose level is stable.
  • the test should not be performed if the patient is stressed or has an illness that can have an effect on the blood glucose levels.
  • the meal that the patient eats during the test should be carefully quantified in ets. This can be done using ets tables published in literature, databases available on the Internet or other products available.
  • the patient's blood glucose level is measured every 30 minutes (or continuosly) after the meal for the next 3 hours using a blood glucose monitor.
  • the maximum value of these blood glucose level measurements will be used to calculate the rise in blood glucose level 13 caused by the meal.
  • the level rise 13 is the difference between the maximum level 12 and the blood glucose level prior to the meal 14.
  • ets sensitivity (EC) can then be calculated.
  • ets sensitivity (EC) for higher values of ets intake can also be calculated by eating more ets after the blood sugar stabilized after the meal. Equation (2) can then be used to calculate ets sensitivity (EC) at higher levels of ets intake.
  • the effect that insulin has on the decrease of blood glucose concentration for the diabetic can also be approximated by a linear function.
  • the sensitivity of insulin value IC can be calculated performing the second part of the test procedure.
  • the insulin sensitivity value (IC) gives a good indication of how resistant the patient is to. insulin. Better insulin sensitivity values imply low insulin resistance and vice versa.
  • FIG. 3 shows a typical blood glucose response of a Type I diabetic after administering short acting insulin. This response illustrates an initial high blood glucose level being lowered by the administering short acting insulin.
  • insulin is only injected after the blood glucose level has stabilized after the meal.
  • the time of the short acting insulin injection is taken at 0 minutes (19).
  • the insulin dosage or units to be injected should be sufficient to lower blood glucose level back to an acceptable value.
  • the patient's blood glucose level is measured right before the injection and every 30 minutes (or continuosly) thereafter.
  • the minimum value where the blood glucose level stabilizes is used to calculate the decrease in blood glucose level. This is merely the difference 17 between the stabilized blood glucose level after the meal 16 and the stabilized blood glucose level after the insulin injection 18.
  • the insulin sensitivity can then be calculated. _ Decrease in bloodsugar level resulting from insulin injection number of units insulin injected
  • the SSpredicted value as the desire blood glucose level BSdesired and calculate the Ui nsu ii n needed.
  • the effect of exercise can also be introduced in a similar way by quantifying exercise in terms of ets exercised. This will result in a reduction in blood glucose level per unit exercise performed. Different exercises can be quantified in terms of ets ex e r c i sed . The sensitivity E X C will be determined by the decrease in blood glucose level per unit ETS eX ercised. If exercise is to be considered Equation 7 can be altered.
  • StS fo be eaten ⁇ (E ⁇ O. ⁇ ifS exercised " S ⁇ current + SS wa nted ) ' E (9)
  • the diabetic knows what the effect of a certain amount of food and exercise will be on his/her blood sugar, and the diabetic knows what effect one unit of insulin will have on his/her blood glucose level, it becomes an easy task to calculate the required insulin dosage. Therefore it is important to calculate the ets and insulin sensitivity values accurately using the device.
  • Fig. 1 shows the block diagram for the mobile communication device based insulin bolus calculation application.
  • Said application consists of an input means , processing means, storage means and output means.
  • Input means receives from the user current blood glucose values, selections of food and beverages to be consumed, user specific parameters such as sensitivities to ets and isulin and othe body characteristics, selections of exercises to be performed as well as the duration and time of activities.
  • Said storage means stores exercise, food and medication databases as well as user specific parameters and a log of all activities including food intake, exercises, medication and time thereof.
  • Equations 7, 8 and 9 is executed by the processing means by taking the inputs and stored information into account. More complex versions of these equations are executed by the processing means to take into account the time lapsed since events, medication release and absorbtion rates as well as effects on meals altering the gucose absorbtion of these meals.
  • Said output means is responsible for displaying suggestions such as an insulin bolus dosage, amount of carbohydrates to be consumed and other recommendations regarding blood glucose control.
  • the output means is also responsible for the general display of information such as the content of the databases and other information or instructions deemed necessary.

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Primary Health Care (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • General Business, Economics & Management (AREA)
  • Business, Economics & Management (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne un dispositif permettant une meilleure surveillance de la glycémie. Ce dispositif est constitué d'une application mise en oeuvre sur un dispositif de communications mobiles utilisant des algorithmes de prédiction de la glycémie et de calcul du bol d'insuline. L'invention capture par ses organes d'entrée l'heure et les détails d'événements tels que la prise d'aliments, l'exercice physique, la prise de médicaments (insuline), la glycémie, et d'autres paramètres spécifiques de l'utilisateurs tels que la sensibilité à l'insuline et aux glucides, le poids, le niveau d'activité, etc. L'invention utilise alors normalement les algorithmes pour calculer le type et l'importance de la mesure correctrice à prendre pour agir sur la glycémie. La suggestion s'affiche sur l'organe de sortie du dispositif. La configuration normale de l'invention est un téléphone mobile exécutant un applicatifs utilisant les ressources du dispositif de communications. Pour introduire l'information, on utilise le clavier, les résultats s'affichant à l'écran du dispositif de communications mobiles. L'utilisation régulière du dispositif permet une meilleure gestion du régime insulinique par l'utilisateur, ce qui permet une meilleure gestion de la glycémie, et réduit d'autant les complications diabétiques associées à l'hyperglycémie comme à l'hypoglycémie.
PCT/ZA2005/000040 2004-02-19 2005-02-18 Calculateur de bol d'insuline pour dispositif de communications mobiles WO2005081171A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA2004/1345 2004-02-19
ZA200401345 2004-02-19

Publications (2)

Publication Number Publication Date
WO2005081171A2 true WO2005081171A2 (fr) 2005-09-01
WO2005081171A3 WO2005081171A3 (fr) 2006-09-14

Family

ID=34887953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ZA2005/000040 WO2005081171A2 (fr) 2004-02-19 2005-02-18 Calculateur de bol d'insuline pour dispositif de communications mobiles

Country Status (1)

Country Link
WO (1) WO2005081171A2 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016050A1 (fr) * 2007-08-02 2009-02-05 Novo Nordisk A/S Estimation d'un paramètre nutritionnel pour assister une administration d'insuline
WO2010062010A1 (fr) * 2008-11-26 2010-06-03 동진메디칼 주식회사 Dispositif de mesure du taux de glycémie comprenant une fonction de contrôle du taux de glycémie, et procédé de commande de celui-ci
WO2014008574A1 (fr) * 2012-07-11 2014-01-16 Thomson Caren Frances Procédé, système et appareil pour déterminer des dosages d'insuline pour les diabétiques
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US20160038675A1 (en) * 2014-08-06 2016-02-11 Bigfoot Biomedical, Inc. Infusion pump assembly and method
US9483619B2 (en) 2012-09-11 2016-11-01 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
US9892234B2 (en) 2014-10-27 2018-02-13 Aseko, Inc. Subcutaneous outpatient management
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US10529454B2 (en) 2014-10-17 2020-01-07 Bradley E. Kahlbaugh Human metabolic condition management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176183A1 (en) * 2001-04-02 2003-09-18 Therasense, Inc. Blood glucose tracking apparatus and methods
US20030195404A1 (en) * 2000-09-22 2003-10-16 Knobbe Edward J. Method and apparatus for real-time control of physiological parameters

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030195404A1 (en) * 2000-09-22 2003-10-16 Knobbe Edward J. Method and apparatus for real-time control of physiological parameters
US20030176183A1 (en) * 2001-04-02 2003-09-18 Therasense, Inc. Blood glucose tracking apparatus and methods

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016050A1 (fr) * 2007-08-02 2009-02-05 Novo Nordisk A/S Estimation d'un paramètre nutritionnel pour assister une administration d'insuline
EP2023256A1 (fr) * 2007-08-02 2009-02-11 Novo Nordisk A/S Surveillance de l'administration de médicaments
WO2010062010A1 (fr) * 2008-11-26 2010-06-03 동진메디칼 주식회사 Dispositif de mesure du taux de glycémie comprenant une fonction de contrôle du taux de glycémie, et procédé de commande de celui-ci
WO2014008574A1 (fr) * 2012-07-11 2014-01-16 Thomson Caren Frances Procédé, système et appareil pour déterminer des dosages d'insuline pour les diabétiques
US9483619B2 (en) 2012-09-11 2016-11-01 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US11733196B2 (en) 2012-09-11 2023-08-22 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US11131643B2 (en) 2012-09-11 2021-09-28 Aseko, Inc. Method and system for optimizing insulin dosages for diabetic subjects
US10629294B2 (en) 2012-09-11 2020-04-21 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US10410740B2 (en) 2012-09-11 2019-09-10 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US10102922B2 (en) 2012-09-11 2018-10-16 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9773096B2 (en) 2012-09-11 2017-09-26 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9811638B2 (en) 2012-09-11 2017-11-07 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9965596B2 (en) 2012-09-11 2018-05-08 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US11490837B2 (en) 2014-01-31 2022-11-08 Aseko, Inc. Insulin management
US11158424B2 (en) 2014-01-31 2021-10-26 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US12127831B2 (en) 2014-01-31 2024-10-29 Aseko, Inc. Insulin management
US9965595B2 (en) 2014-01-31 2018-05-08 Aseko, Inc. Insulin management
US9892235B2 (en) 2014-01-31 2018-02-13 Aseko, Inc. Insulin management
US9710611B2 (en) 2014-01-31 2017-07-18 Aseko, Inc. Insulin management
US12027266B2 (en) 2014-01-31 2024-07-02 Aseko, Inc. Insulin management
US11621074B2 (en) 2014-01-31 2023-04-04 Aseko, Inc. Insulin management
US10255992B2 (en) 2014-01-31 2019-04-09 Aseko, Inc. Insulin management
US11857314B2 (en) 2014-01-31 2024-01-02 Aseko, Inc. Insulin management
US11804300B2 (en) 2014-01-31 2023-10-31 Aseko, Inc. Insulin management
US9604002B2 (en) 2014-01-31 2017-03-28 Aseko, Inc. Insulin management
US10453568B2 (en) 2014-01-31 2019-10-22 Aseko, Inc. Method for managing administration of insulin
US11783945B2 (en) 2014-01-31 2023-10-10 Aseko, Inc. Method and system for insulin infusion rate management
US10535426B2 (en) 2014-01-31 2020-01-14 Aseko, Inc. Insulin management
US9504789B2 (en) 2014-01-31 2016-11-29 Aseko, Inc. Insulin management
US10811133B2 (en) 2014-01-31 2020-10-20 Aseko, Inc. System for administering insulin boluses to a patient
US11468987B2 (en) 2014-01-31 2022-10-11 Aseko, Inc. Insulin management
US11783946B2 (en) 2014-01-31 2023-10-10 Aseko, Inc. Method and system for insulin bolus management
US11081233B2 (en) 2014-01-31 2021-08-03 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US11311213B2 (en) 2014-01-31 2022-04-26 Aseko, Inc. Insulin management
US10994078B2 (en) 2014-08-06 2021-05-04 Bigfoot Biomedical, Inc. Infusion pump assembly and method
US20160038675A1 (en) * 2014-08-06 2016-02-11 Bigfoot Biomedical, Inc. Infusion pump assembly and method
US10137246B2 (en) * 2014-08-06 2018-11-27 Bigfoot Biomedical, Inc. Infusion pump assembly and method
US12053615B2 (en) 2014-08-06 2024-08-06 Insulet Corporation Infusion pump assembly and method
US10529454B2 (en) 2014-10-17 2020-01-07 Bradley E. Kahlbaugh Human metabolic condition management
US11678800B2 (en) 2014-10-27 2023-06-20 Aseko, Inc. Subcutaneous outpatient management
US11694785B2 (en) 2014-10-27 2023-07-04 Aseko, Inc. Method and dosing controller for subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
US10403397B2 (en) 2014-10-27 2019-09-03 Aseko, Inc. Subcutaneous outpatient management
US12023127B2 (en) 2014-10-27 2024-07-02 Aseko, Inc. Subcutaneous outpatient management
US10128002B2 (en) 2014-10-27 2018-11-13 Aseko, Inc. Subcutaneous outpatient management
US9892234B2 (en) 2014-10-27 2018-02-13 Aseko, Inc. Subcutaneous outpatient management
US11574742B2 (en) 2015-08-20 2023-02-07 Aseko, Inc. Diabetes management therapy advisor
US10380328B2 (en) 2015-08-20 2019-08-13 Aseko, Inc. Diabetes management therapy advisor
US12040096B2 (en) 2015-08-20 2024-07-16 Aseko, Inc. Diabetes management therapy advisor
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor

Also Published As

Publication number Publication date
WO2005081171A3 (fr) 2006-09-14

Similar Documents

Publication Publication Date Title
US11490837B2 (en) Insulin management
US20240212819A1 (en) Systems for Optimizing A Patient's Insulin Dosage Regimen
US11246986B2 (en) Integrated closed-loop medication delivery with error model and safety check
Šoupal et al. Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study
EP2023256A1 (fr) Surveillance de l'administration de médicaments
Riddell et al. Exercise in adults with type 1 diabetes mellitus
US10194839B2 (en) Method and device for assessment of a series of glucose concentration values of a body fluid of a diabetic for adjustment of insulin dosing
Longo et al. Glycemic control in people with type 1 diabetes using a hybrid closed loop system and followed by telemedicine during the COVID-19 pandemic in Italy
WO2006079124A2 (fr) Appareil et procede servant a prevoir l'effet de denrees alimentaires ingerees ou d'exercice sur le taux de glycemie d'un patient et a suggerer une action corrective
WO2005081171A2 (fr) Calculateur de bol d'insuline pour dispositif de communications mobiles
Farman et al. Stability analysis and control of the glucose insulin glucagon system in humans
CN115645679A (zh) 基于线性模型的自适应闭环控制方法
WO2005081173A1 (fr) Regle a calcul pour la surveillance de la glycemie
Crawford et al. Efficacy of insulin pump therapy: mealtime delivery is the key factor
Doran Modelling and control of hyperglycemia in critical care patients
Peters et al. Insulin pump therapy
Owen Pediatric pumps
US20240242810A1 (en) Insulin on board for glucose sensitive insulin
CA2860796C (fr) Procede, systeme et appareil de calcul du ratio glucides-insuline a l'usage des diabetiques
Wong Model-Based Therapeutics for Type 1 Diabetes Mellitus
US20240123148A1 (en) Control device for determining a recommendation value of a control parameter of a fluid infusion device
EP3960219A1 (fr) Techniques de détermination de formulations d'insuline dans un système d'administration d'insuline automatisé
WO2005081172A1 (fr) Dispositif pour caracteriser la sensibilite a l'insuline et aux glucides
Selvan et al. Insulin pump–A review
Pejtersen et al. Detection of events using continuous glucose monitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase